Want to see OGN full AI Analyst Report?
OGN Stock Chart & Stats
$9.76
-$0.16(-1.02%)
At close: 4:00 PM EST
$9.76
-$0.16(-1.02%)
Day’s Range― - ―
52-Week Range$5.69 - $13.60
Previous CloseN/A
Volume728.75K
Average Volume (3M)2.37M
Market Cap
$3.55B
Enterprise Value$9.03K
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$8.57B
Price to Earnings (P/E)14.2
Beta0.95
Next Earnings
Aug 11, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend Yield0.59%
Share Statistics
EPS (TTM)0.95
Shares Outstanding262,609,440
10 Day Avg. Volume2,567,712
30 Day Avg. Volume2,365,295
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.47
Price to Sales (P/S)0.30
P/FCF Ratio3.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside43.44% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)3.39
Revenue Forecast (FY)$6.13B
Bulls Say, Bears Say
Bulls Say
Divestiture ProceedsDivestiture of the JADA System for roughly $440 million plus up to $25 million in milestone payments strengthens cash reserves and reduces exposure to non-core assets.
Leverage TargetCompany commitment to keep net debt to adjusted EBITDA below four times signals a focus on deleveraging that could improve credit perception and investor confidence.
Bears Say
Dividend Policy And SentimentA surprising dividend cut increased investor concern about cash allocation and may prolong negative sentiment absent a clear capital-allocation plan from management.
Governance And ComplianceInvestigation finding that U.S. wholesalers were encouraged to overpurchase Nexplanon, followed by the CEO resignation, raises governance and compliance concerns that could attract regulatory scrutiny and erode trust.
Revenue OutlookLowered revenue guidance driven by U.S. policy headwinds for Nexplanon and softness in the respiratory franchise highlights near-term revenue risk and may pressure growth expectations.
Organon News
OGN FAQ
What was Organon & Co.’s price range in the past 12 months?
Organon & Co. lowest stock price was $5.69 and its highest was $13.60 in the past 12 months.
What is Organon & Co.’s market cap?
Organon & Co.’s market cap is $3.55B.
When is Organon & Co.’s upcoming earnings report date?
Organon & Co.’s upcoming earnings report date is Aug 11, 2026 which is in 22 days.
How were Organon & Co.’s earnings last quarter?
Organon & Co. released its earnings results on Apr 30, 2026. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.829 by -$0.119.
Is Organon & Co. overvalued?
According to Wall Street analysts Organon & Co.’s price is currently Undervalued.
Does Organon & Co. pay dividends?
Organon & Co. pays a Quarterly dividend of $0.02 which represents an annual dividend yield of 0.59%. See more information on Organon & Co. dividends here
What is Organon & Co.’s EPS estimate?
Organon & Co.’s EPS estimate is 0.9.
How many shares outstanding does Organon & Co. have?
Organon & Co. has 262,609,440 shares outstanding.
What happened to Organon & Co.’s price movement after its last earnings report?
Organon & Co. reported an EPS of $0.71 in its last earnings report, missing expectations of $0.829. Following the earnings report the stock price went down -0.676%.
Which hedge fund is a major shareholder of Organon & Co.?
Currently, no hedge funds are holding shares in OGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.00 (43.44% Upside)
$14.00 (43.44% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $352.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.49%
12-Months-Change
Fundamentals
Return on Equity
0.59%
Trailing 12-Months
Asset Growth
-1.22%
Trailing 12-Months
Company Description
Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
OGN Stock 12 Month Forecast
Average Price Target
$14.00
▲(43.44% Upside)
Technical Analysis
Ownership Overview
0.34% Insiders
17.94% Mutual Funds
0.21% Other Institutional Investors
58.39% Public Companies and
Individual Investors